Healthcare consultancy Prescient Healthcare Group has completed the integration of recently acquired businesses Uptake and Dolon under a single global Prescient brand, creating an organisation of more than 550 specialists supporting life sciences companies across commercial strategy, competitive intelligence, medical affairs and value, pricing and access.

The rebrand marks the final stage of integrating the three businesses following Prescient’s acquisitions of Uptake and Dolon, providing clients with a single point of access to expertise spanning the pharmaceutical product life cycle.

Jason McKenna, CEO of Prescient, said: “Over the past several months, the Prescient, Dolon and Uptake teams have been working together to solve increasingly complex challenges for clients. Bringing everything together under the Prescient name reflects how the platform works today, as one integrated organisation combining specialist expertise across commercial, medical and market access disciplines.”

The unified business supports pharmaceutical and biotechnology companies from early clinical development through product launch and life cycle management. Prescient said the integrated structure enables multidisciplinary teams to address increasingly connected commercial, scientific and market access challenges facing the industry.

The evolution reflects a broader way of partnering with life sciences organisations as they face increasingly interconnected scientific, commercial, medical and market access decisions. As a strategy-to-impact partner, Prescient helps clients move from insight, to strategy, to implementation, connecting the expertise needed at each stage of an asset’s journey, from early development through launch and life cycle optimisation.

The unified Prescient brand also simplifies how clients engage with the business. Rather than navigating multiple brands, clients now access one connected organisation with specialist expertise across Commercial Strategy and Planning; Competitive Strategy; Medical Affairs and Real-World Evidence; and Value, Pricing and Access

The integration follows a period of operational alignment between the three organisations and establishes a single global Prescient brand across its seven international offices.

Havas Lynx has announced that Claire Knapp, CEO of Havas Lynx UK (pictured top left), will expand her leadership remit to oversee Havas Lynx New York.

Knapp has spent more than 15 years at Havas Lynx, pioneering the agency’s strategic offerings, and has held a series of leadership roles spanning strategy, innovation, client partnership and business growth. Throughout her career, she has led global, regional and local initiatives across creative and media disciplines, helping shape work across multiple therapeutic areas and advancing thought leadership on healthcare professional well-being, health misinformation, sustainability and patient-centricity. As part of her expanded remit, Knapp will be based in New York while dividing her time between the US and UK.

Dan Rubin, Group President, North America, Havas Health Network, said: “Claire’s strategic vision, entrepreneurial mindset and commitment to leveraging creativity to deliver impact that matters have helped drive the agency’s evolution, growth and reputation for excellence. Claire’s leadership, coupled with her passion for innovation and talent development, positions Havas Lynx strongly for its next chapter.”

Knapp commented: “Healthcare continues to evolve at an incredible pace, creating new opportunities for creativity, innovation and connection. I’m excited to build on the strong foundation we’ve created, alongside our teams around the world.”